UCB: positive drug developments in the US and China
(CercleFinance.com) - Belgium's UCB and US partner Amgen on Monday announced that a US Food and Drug Administration (FDA) committee will review data supporting the biologics license application for investigational monoclonal antibody Evenity for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on 16 January.
The biopharmaceutical company also said that it has received an import drug license from the National Drug Administration of China to market Vimpat for people with epilepsy in China.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The biopharmaceutical company also said that it has received an import drug license from the National Drug Administration of China to market Vimpat for people with epilepsy in China.
Copyright (c) 2018 CercleFinance.com. All rights reserved.